Fosun Pharmaceutical to Set Up Parallel Fund Structure

MT Newswires Live04-01

Shanghai Fosun Pharmaceutical (Group) (SHA:600196, HKG:2196) plans to establish a parallel fund structure, which will consist of two funds that will invest in early-stage healthcare innovation projects, according to a Shanghai bourse filing on Wednesday.

The Tianjin Phase II Fund and the Hangzhou Fund will each have a target size of 1 billion yuan.

The pharmaceutical company will be a limited partner, investing 288 million yuan and 10 million yuan in Tianjin Phase II through two subsidiaries, and 348 million yuan in Hangzhou Fund through another designated subsidiary.

Fosun's Hong Kong shares rose 3% and Shanghai shares gained 2% during the morning trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2624566319?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-01 11:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2624566319","market":"hk","top_or_hot":-1,"title":"Fosun Pharmaceutical to Set Up Parallel Fund Structure","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/SFOSF\">Shanghai Fosun</a> Pharmaceutical (Group) (SHA:600196, HKG:2196) plans to establish a parallel fund structure, which will consist of two funds that will invest in early-stage healthcare innovation projects, according to a Shanghai bourse filing on Wednesday.</p><p>The Tianjin Phase II Fund and the Hangzhou Fund will each have a target size of 1 billion yuan.</p><p>The pharmaceutical company will be a limited partner, investing 288 million yuan and 10 million yuan in Tianjin Phase II through two subsidiaries, and 348 million yuan in Hangzhou Fund through another designated subsidiary.</p><p>Fosun's Hong Kong shares rose 3% and Shanghai shares gained 2% during the morning trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fosun Pharmaceutical to Set Up Parallel Fund Structure</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFosun Pharmaceutical to Set Up Parallel Fund Structure\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-04-01 11:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/SFOSF\">Shanghai Fosun</a> Pharmaceutical (Group) (SHA:600196, HKG:2196) plans to establish a parallel fund structure, which will consist of two funds that will invest in early-stage healthcare innovation projects, according to a Shanghai bourse filing on Wednesday.</p><p>The Tianjin Phase II Fund and the Hangzhou Fund will each have a target size of 1 billion yuan.</p><p>The pharmaceutical company will be a limited partner, investing 288 million yuan and 10 million yuan in Tianjin Phase II through two subsidiaries, and 348 million yuan in Hangzhou Fund through another designated subsidiary.</p><p>Fosun's Hong Kong shares rose 3% and Shanghai shares gained 2% during the morning trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0188","symbol_name":"融资融券","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2624566319","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2624566319","pubTimestamp":1775015336,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Shanghai Fosun Pharmaceutical   plans to establish a parallel fund structure, which will consist of two funds that will invest in early-stage healthcare innovation projects, according to a Shanghai bourse filing on Wednesday.The Tianjin Phase II Fund and the Hangzhou Fund will each have a target size of 1 billion yuan.The pharmaceutical company will be a limited partner, investing 288 million yuan and 10 million yuan in Tianjin Phase II through two subsidiaries, and 348 million yuan in Hangzhou Fund through another designated subsidiary.Fosun's Hong Kong shares rose 3% and Shanghai shares gained 2% during the morning trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600196":"复星医药","BK0188":"融资融券","BK0183":"MSCI概念","BK0012":"证金概念","BK1593":"医美概念股","BK0175":"白马股","BK0196":"行业龙头","BK0187":"一线龙头","BK1191":"制药","BK0096":"民营医院","BK0028":"国家队","BK0060":"抗癌","BK0239":"医药制造","02196":"复星医药","BK1515":"抗疫概念"},"translate_title":"复星医药将设立平行基金结构","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":0.9,"02196":0.9},"content_text":"Shanghai Fosun Pharmaceutical (Group) (SHA:600196, HKG:2196) plans to establish a parallel fund structure, which will consist of two funds that will invest in early-stage healthcare innovation projects, according to a Shanghai bourse filing on Wednesday.The Tianjin Phase II Fund and the Hangzhou Fund will each have a target size of 1 billion yuan.The pharmaceutical company will be a limited partner, investing 288 million yuan and 10 million yuan in Tianjin Phase II through two subsidiaries, and 348 million yuan in Hangzhou Fund through another designated subsidiary.Fosun's Hong Kong shares rose 3% and Shanghai shares gained 2% during the morning trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2624566319","isCrawlerRequest":true}